Latus Pharma ApS: Financial statements 2022
CVR: 36974214
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Latus Pharma ApS (CVR 36974214) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -13,677 and a net result of DKK -13,677 compared with DKK -4,109 the year before. Equity in the 2022 report amounted to DKK 105,052. The solvency ratio was 100%.
- Revenue
- DKK 0
- Gross Profit
- DKK -13,677
- Profit/Loss
- DKK -13,677
- Equity
- DKK 105,052
- Total Assets
- DKK 105,052
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 0 | -14 t. | -14 t. | 105 t. | - |
| 2021 | 0 | -4 t. | -4 t. | 119 t. | - |
| 2020 | 0 | -4 t. | -4 t. | 123 t. | - |
| 2019 | 0 | -4 t. | -4 t. | 127 t. | - |
| 2018 | 0 | -4 t. | -4 t. | 131 t. | - |
Official annual report
Keep an eye on Latus Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Latus Pharma ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK -4,109.
About Latus Pharma ApS
Latus Pharma ApS is a Danish company of the type Anpartsselskab based in Køge, founded in 2015. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Jørgen Wittendorff. The company is owned by Jørgen Wittendorff. In 2025, the company reported revenue of DKK -6,991 and a net result of DKK -6,991 compared with DKK -6,897 the year before. Equity in the 2025 report amounted to DKK 82,569.